On site production of [F]PSMA-1007 using different [F]fluoride activities: practical, technical and economical impact.

Background: Prostate-specific membrane antigen is overexpressed in prostate cancer and it is considered a good target for positron emission tomography/computed tomography imaging of primary cancer and recurrent/metastatic disease, as well as for radioligand therapy. Different PSMA-analogues labeled with [Ga]gallium have been investigated, showing excellent imaging properties; however, only small amounts can be produced for each radiolabeling. Recently, a [F]fluoride labeled PSMA-inhibitor, [F]PSMA-1007, has been introduced, and it has ensured large-scale productions, overcoming this limitation of [Ga]PSMAs.

Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors.

The recently reported CXCR4 antagonist (Ac-Arg-Ala-[DCys-Arg-2Nal-His-Pen]-COH) was investigated as a molecular scaffold for a CXCR4-targeted positron emission tomography (PET) tracer. Toward this end, was functionalized with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononanetriacetic acid (NOTA). On the basis of convincing affinity data, both tracers, [Ga]NOTA analogue ([Ga]-) and [Ga]DOTA analogue ([Ga]-), were evaluated for PET imaging in "" models of CHO-hCXCR4 and Daudi lymphoma cells.